<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BIVALIRUDIN</span><br/>(bi-val'i-ru-den)<br/><span class="topboxtradename">Angiomax<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">thrombin inhibitor</span><br/><b>Prototype: </b>Lepirudin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Direct inhibitor of thrombin similar to lepirudin. Capable of inhibiting the action of both free and clot-bound thrombin.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reversibly binds to the thrombin active site, thereby blocking the thrombogenic activity of thrombin.</p>
<h1><a name="uses">Uses</a></h1>
<p>Used with aspirin as an anticoagulant in patients undergoing PTCA.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Anticoagulant used in heparin-induced thrombocytopenia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bivalirudin; cerebral aneurysm, intracranial hemorrhage; patients with increased risk of bleeding (e.g.,
         recent surgery, trauma, CVA); pregnancy (category B), lactation. Safety and efficacy in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Asthma or allergies; blood dyscrasia or thrombocytopenia; GI ulceration, serious hepatic disease; hypertension, renal impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anticoagulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.75 mg/kg bolus followed by 1.75 mg/kg/h for the duration of the procedure, may continue at 0.2 mg/kg/h up to 20 h if needed; intended for use with aspirin 300325 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct/</span><span class="methodtype">Continuous:</span> Push (bolus dose) and initial 4-h continuous infusion: Reconstitute each 250 mg vial with 5 mL of sterile water for injection;
                  gently swirl until dissolved. Further dilute each reconstituted vial in 50 mL of D5W or NS to yield 5 mg/mL.   <span class="methodtype">Continuous:</span> Subsequent infusions are low-rate continuous. Reconstitute each 250 mg vial as above. Further dilute each reconstituted vial
                  in 500 mL of D5W or NS to yield 0.50 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Give bolus dose 0.75 mg/kg (see manufacturer's dosing table) IV push.   <span class="methodtype">Continuous:</span> Give 1.75 mg/kg/h for the duration of the PTCA procedure. Subsequent doses, give 0.2 mg/kg/h for up to 20 h as ordered.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted vials refrigerated at 2°8° C (35.6°46.4° F) for up to 24 h. Store diluted
            concentrations between 0.5 mg/mL and 5 mg/mL at room temperature, 15°30° C (59°86° F), for
            up to 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Back pain,</span> pain, fever. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span> hypertension, bradycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, dyspepsia, abdominal pain. <span class="typehead">Hematologic:</span> Bleeding. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> anxiety, nervousness. <span class="typehead">Urogenital:</span> Urinary retention, pelvic pain. <span class="typehead">Other:</span> Injection site pain. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 1 h. <span class="typehead">Distribution:</span> No protein binding. <span class="typehead">Metabolism:</span> Proteolytic cleavage and renal metabolism. <span class="typehead">Elimination:</span> Renal. <span class="typehead">Half-Life:</span> 25 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiovascular status carefully during therapy.</li>
<li>Monitor for and report S&amp;S of bleeding: Ecchymosis, epistaxis, GI bleeding, hematuria, hemoptysis.</li>
<li>Patients with history of GI ulceration, hypertension, recent trauma or surgery are at increased risk for bleeding.</li>
<li>Monitor neurologic status and report immediately: focal or generalized deficits.</li>
<li>Lab tests: Baseline and periodic ACT (activated clotting time), APTT, PT, INR, thrombin time (TT), plasma fibrinopeptide A
            (especially in unstable angina), platelet count, Hgb and Hct; periodic serum creatinine, stool for occult blood, urinalysis.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following immediately: Unexplained back or stomach pain; black, tarry stools; blood in urine, coughing up
            blood; difficulty breathing; dizziness or fainting spells; heavy menstrual bleeding; nosebleeds; unusual bruising or bleeding
            at any site.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>